Adamis on go to start late-stage studies of APC-1000 in asthma

|About: Adamis Pharmaceuticals... (ADMP)|By:, SA News Editor

Adamis Pharmaceuticals (NASDAQ:ADMP) announces that the FDA has signed off on Phase 3 clinical trials assessing APC-1000 in asthma patients. The studies should launch later this year.

APC-1000 is a metered dose inhaler containing the corticosteroid beclomethasone. The company says its value proposition is lower systemic absorption with comparable efficacy to currently available corticosteroids.

Shares are up 1% premarket.

Subscribe for full text news in your inbox